NCT01442155View on ClinicalTrials.gov

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

CompletedOBSERVATIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Colorectal Cancer
Interventions
DRUG

Capecitabine

Administered according to the Summary of Product Characteristics.

BIOLOGICAL

Oxaliplatin

Administered according to the Summary of Product Characteristics.

Trial Locations (9)

975 17

Banská Bystrica

812 50

Bratislava

833 10

Bratislava

04001

Košice

036 59

Martin

950 01

Nitra

058 01

Poprad

081 81

Prešov

03426

Ružomberok

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01442155 - An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer | Biotech Hunter | Biotech Hunter